Q-omics provides the consensus-scored PCDH9 profile across patient tissues and cancer cell-line models. PCDH9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PCDH9 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, PCDH9 RNA expression shows 16,975 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KIRC, and THYM as cancer lineages where PCDH9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDH9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDH9 survival associations across molecular data types. PCDH9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDH9 RNA expression–survival associations across cancer types. High PCDH9 expression shows unfavorable associations in UCEC, BLCA, KIRP, OV and COAD, but favorable associations in KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PCDH9 RNA expression.
This table summarizes PCDH9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PCDH9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDH9 shows lower tumor expression in KIRC, KICH, KIRP, LUAD, LUSC and BRCA. The KIRC box plot shows higher PCDH9 RNA expression in normal versus tumor tissue (log2 FC = −1.470, t-test p < 0.001).
This table shows molecular features associated with PCDH9 in patient tissues and cancer cell lines. In patient samples, PCDH9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDH9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
